

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Twitty Christopher</u> (Last) (First) (Middle) <u>11250 EL CAMINO REAL, SUITE 100</u> (Street) <u>SAN DIEGO CA 92130</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>04/23/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Skye Bioscience, Inc. [SKYE]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Scientific Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	81,242 ⁽¹⁾	D	

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(2)	09/29/2033	Common Stock	17,004	3.5	D	
Stock Option (Right to Buy)	(3)	02/28/2034	Common Stock	75,000	14.56	D	
Stock Option (Right to Buy)	(4)	08/25/2033	Common Stock	7,100	3.5	D	
Stock Option (Right to Buy)	(5)	10/28/2034	Common Stock	200,000	5.15	D	
Stock Option (Right to Buy)	(6)	02/24/2035	Common Stock	150,000	2.89	D	
Stock Option (Right to Buy)	(7)	01/05/2033	Common Stock	12,000	4.25	D	

Explanation of Responses:

1. Includes (a) 14,060 restricted stock unit ("RSU") awards that vests upon the company achieving a market capitalization of \$500 million or more and (b) 25,000 RSUs that vest upon the achievement of the following performance milestones: (i) 25% vests upon the company achieving a market capitalization of \$750 million and a stock price of \$20.00 per share, (ii) an additional 25% vests upon the company achieving a market capitalization of \$1 billion and a stock price of \$25.00 per share, (iii) an additional 25% vests upon the company achieving a market capitalization of \$1.25 billion and a stock price of \$30.00 per share and (iv) an additional 25% vests if the company achieves a market capitalization of \$1.5 billion or greater and a stock price of \$35.00 per share.
2. The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023.
3. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024.
4. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023.
5. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024.
6. The stock option vests in equal monthly installments over the one year period beginning February 21, 2025.
7. The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Kaitlyn Arsenault, as Attorney-in-Fact 04/25/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that the undersigned hereby constitutes and appoints each of Kaitlyn Arsenault and Punit Dhillon, or any of them signing singly, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Skye Bioscience, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 23rd day of April, 2025.

/s/ Christopher Twitty
Signature

Christopher Twitty